52 completed, 5 terminated, 3 unknown, 2 recruiting. 32 Phase 3, 15 Phase 4, 7 Phase 1, 7 Phase 2, 3 Not applicable.
Follow lixisenatide: new trials by email Literature Review of lixisenatide trials Research Report on lixisenatide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents iGlarLixi (insulin glargine/lixisenatide), standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs) - Type 2 Diabetes | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 1316 | 2025-12-13 | 2026-07-07 |
| Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes lixisenatide + glargine, Intensive insulin therapy - Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia | Phase 4 | Enrolling by invitation | Medical University of Warsaw | 100 | 2025-07-10 | 2025-09-19 |
| A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus iGlarLixi (insulin glargine/lixisenatide) - Type 2 Diabetes | Phase 4 | Completed | Sanofi | 105 | 2025-01-06 | 2026-07-10 |
| iGlarLixi CGM Study in Chinese T2D Individuals After OADs iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine) - Type 2 Diabetes (T2D) | Phase 4 | Recruiting | Sanofi | 678 | 2024-12-10 | 2026-03-17 |
| The Effect of Lixisenatide on the Effect of Pituitary Hormones Placebo, Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector - Healthy, Type 1 Diabetes | Phase 4 | Unknown | University of Tartu | 10 | 2023-04-17 | 2023-06-12 |
| iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) Insulin glargine/Lixisenatide, IDegAsp, Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 582 | 2022-07-07 | 2025-09-24 |
| Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus Insulin glargine/Lixisenatide - Type 2 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 124 | 2022-01-27 | 2025-09-09 |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA - Cardiovascular Events, Type2 Diabetes | Active not recruiting | Brigham and Women's Hospital | 781430 | 2021-08-01 | 2026-08-13 | |
| Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 426 | 2019-02-19 | 2022-07-19 |
| Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Lixisenatide (AVE0010) - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 878 | 2019-02-15 | 2022-07-19 |
| The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians Basal insulin glargine and lixisenatide, Basal insulin Basaglar/Lantus + gliclazide MR, Metformin - Diabetes Mellitus, Type 2 | Phase 4 | Completed | LMC Diabetes & Endocrinology Ltd. | 119 | 2018-10-02 | 2021-02-25 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010), INSULIN GLARGINE (HOE901), Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 247 | 2018-06-19 | 2022-04-25 |
| Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease Lixisenatide, placebo - Parkinson Disease | Phase 2 | Completed | University Hospital, Toulouse | 156 | 2018-06-13 | 2025-11-28 |
| Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy - Type 2 Diabetes Mellitus | Phase 3 | Terminated | Sanofi | 241 | 2018-02-20 | 2022-03-28 |
| Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi iGlarLixi, Insulin Glargine, Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Population Health Research Institute | 161 | 2017-06-27 | 2020-11-13 |
| A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) Lixisenatide (AVE0010), Placebo, Basal Insulin - Type 2 Diabetes Mellitus | Phase 1 | Completed | Sanofi | 23 | 2017-05-17 | 2022-04-25 |
| Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan Lixisenatide (AVE0010), Sulfonylurea, metformin - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Sanofi | 184 | 2017-02-23 | 2022-04-25 |
| Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog Lixisenatide, Basal insulins - Diabetes Mellitus Type 2 | Phase 4 | Terminated | Laniado Hospital | 2 | 2016-07-12 | 2017-04-07 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 514 | 2016-07-06 | 2022-03-25 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Oral anti-diabetic drugs - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 521 | 2016-05-23 | 2020-06-16 |
Showing 20 of 64. Sign in to see all of them.
Diabetes Mellitus, Type 2 (53) · Diabetes Mellitus (8) · Hyperglycemia (8) · Insulin Resistance (3) · Diabetes Mellitus, Type 1 (2) · Acute Coronary Syndrome (1) · Diabetic Nephropathies (1) · Gastroparesis (1) · Hypoglycemia (1) · Kidney Diseases (1) · Motor Activity (1) · Parkinson Disease (1)
Sanofi (45) · Amsterdam UMC, location VUmc (1) · Brigham and Women's Hospital (1) · Erasme University Hospital (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · LMC Diabetes & Endocrinology Ltd. (1) · Laniado Hospital (1) · Lund University (1) · Medical University of Vienna (1) · Medical University of Warsaw (1) · Novo Nordisk A/S (1) · Population Health Research Institute (1) · Profil Institut für Stoffwechselforschung GmbH (1) · Royal Adelaide Hospital (1) · Seoul National University Hospital (1)
United States (23) · Germany (21) · Canada (15) · Romania (15) · Mexico (14) · Poland (14) · Russia (14) · Japan (12) · Spain (11) · Ukraine (11) · Chile (10) · France (10) · India (10) · Czechia (9) · Italy (9)
David Russell-Jones, MBBS PhD (1) · Elisabetta Patorno, MD, DrPH (1) · Fariba Shojaee-Moradie, BSc, PhD (1) · Filip K Knop, Assoc. Prof. (1) · Hertzel Gerstein, MD (1) · Juris Meier, MD (1) · Karen L Jones, PhD (1) · Leszek Czupryniak, Prof. Dr. hab.n.med. (1) · Margot Umpleby, BA, PhD (1)
PMID 39963952, PMID 29974618, PMID 31956422, PMID 36809495, PMID 23628617, PMID 25130920, PMID 27252787, PMID 27267268, PMID 27319011, PMID 29923298, PMID 30550345, PMID 31114694, PMID 31848983, PMID 36999231, PMID 17098089, PMID 17622601, PMID 20722676, PMID 22432104, PMID 22564709, PMID 23368510, PMID 23524641, PMID 23536584, PMID 23537041, PMID 23564915, PMID 23627775, PMID 23645885, PMID 23698396, PMID 24117597, PMID 24236828, PMID 24639432, PMID 24650952, PMID 25012990, PMID 25887358, PMID 26039935, PMID 26342556, PMID 26537183, PMID 26630143, PMID 27222510, PMID 27284114, PMID 27311491, PMID 27527848, PMID 27650977, PMID 28124820, PMID 28188240, PMID 28345162, PMID 28357772, PMID 28386990, PMID 28432746, PMID 28449402, PMID 28554908
2009 (2), 2008 (1), 2014 (1)